The know-how of producing the Huaman Papilloma Virus (HPV) vaccine is among the most sophisticated and most modern technologies in the world, something that an Iranian company has acquired.
The clinical trail phase of the vaccine started in July 2019; it was tested on healthy volunteers after passing quality-control tests and preclinical studies.
Containing proteins of HPV types 16 and 18, Papilloguard is a recombinant vaccine given to individuals aged between 9 and 26 years to help protect against diseases caused by some types of Human Papilloma Virus (HPV).
After being approved for its effectiveness in increasing the antibody and its safety, the Iranian-made HPV vaccine received approval from the Iran Food and Drug Adminstration (IFDA) to be allowed to enter the market in the winter of 2020.
The research and development process of the product in laboratory and semi-industrial scales took three years.
The Director-General of the company said that the firm has the capacity to produce 15 million doses of vaccine per year and can fully meet the needs of West Asia and North Africa countries.
MNA